Literature DB >> 9371357

Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes.

X R Pan-Zhou1, E Cretton-Scott, X J Zhou, M Y Xie, R Rahmani, R F Schinazi, K Duchin, J P Sommadossi.   

Abstract

AZT-P-ddI is an antiviral heterodimer composed of one molecule of 3'-azido-3'-deoxythymidine (AZT) and one molecule of 2',3'-dideoxyinosine (ddI) linked through their 5' positions by a phosphate bond. The metabolic fate of the dimer was studied with isolated rat, monkey, and human hepatocytes and was compared with that of its component monomers AZT and ddI. Upon incubation of double-labeled [14C]AZT-P-[3H]ddI in freshly isolated rat hepatocytes in suspension at a final concentration of 10 microM, the dimer was taken up intact by cells and then rapidly cleaved to AZT, AZT monophosphate, ddI, and ddI monophosphate. AZT and ddI so formed were then subject to their respective catabolisms. High-performance liquid chromatography analyses of the extracellular medium and cell extracts revealed the presence of unchanged dimer, AZT, 3'-azido-3'-deoxy-5'-beta-D-glucopyranosylthymidine (GAZT), 3'-amino-3'-deoxythymidine (AMT), ddI, and a previously unrecognized derivative of the dideoxyribose moiety of ddI, designated ddI-M. Trace extracellular but substantial intracellular levels of the glucuronide derivative of AMT (3'-amino-3'-deoxy-5'-beta-D-glucopyranosylthymidine [GAMT]) were also detected. Moreover, the extent of the formation of AMT, GAZT, and ddI-M from the dimer was markedly lower than that with AZT and ddI alone by the hepatocytes. With hepatocytes in primary culture obtained from rat, monkey, and human, large interspecies variations in the metabolism of AZT-P-ddI were observed. While GAZT and ddI-M, metabolites of AZT and ddI, respectively, as well as AZT 5'-monophosphate (MP) and ddI-MP were detected in the extracellular media of all species, AMT and GAMT were produced only by rat and monkey hepatocytes. No such metabolites were formed by human hepatocytes. The metabolic fate of the dimer by human hepatocytes was consistent with in vivo data recently obtained from human immunodeficiency virus-infected patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371357      PMCID: PMC164152     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Nucleotide dimers suppress HIV expression in vitro.

Authors:  M Busso; A M Mian; E F Hahn; L Resnick
Journal:  AIDS Res Hum Retroviruses       Date:  1988-12       Impact factor: 2.205

2.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

3.  Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers.

Authors:  G Fabre; R Rahmani; M Placidi; J Combalbert; J Covo; J P Cano; C Coulange; M Ducros; M Rampal
Journal:  Biochem Pharmacol       Date:  1988-11-15       Impact factor: 5.858

4.  Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; J P Sommadossi; V Saalmann; D L Cannon; M Y Xie; G C Hart; G A Smith; E F Hahn
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.

Authors:  J P Sommadossi; D A Gewirtz; R B Diasio; C Aubert; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

6.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.

Authors:  M Baba; R Pauwels; J Balzarini; P Herdewijn; E De Clercq; J Desmyter
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

8.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

9.  Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells.

Authors:  E M Cretton; M Y Xie; R J Bevan; N M Goudgaon; R F Schinazi; J P Sommadossi
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  2 in total

1.  Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.

Authors:  Akihiko Saitoh; Richard H Haas; Robert K Naviaux; Neurita G Salva; Justine K Wong; Stephen A Spector
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

Review 2.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.